Post by BioDuro

👉 April was a busy and dynamic month across the global pharmaceutical landscape, with metabolic disease and oncology driving much of the momentum. Oral GLP-1 therapies in metabolic programs remained in focus, alongside expanding interest in multi-target approaches for metabolic diseases. In oncology, AACR 2026 highlighted the growing complexity of emerging modalities, including ADCs and induced proximity approaches, highlighting the need for tighter integration across chemistry, biology, and translational strategy. Explore our April newsletter for updates on peptide, XDC, and induced proximity modalities, along with formulation development and IND enabling solutions. #DrugDiscovery #MetabolicDisease #Oncology #InducedProximity #ADC #Peptide